- Conditions
- Glaucoma, Ocular Hypertension
- Interventions
- T4090 0.2%, T4090 0.3%, Rhopressa®
- Drug
- Lead sponsor
- Laboratoires Thea
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 24
- States / cities
- Glendale, Arizona • Glendale, California • Inglewood, California + 19 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 229
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Open Angle Glaucoma (OAG), NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)
- Interventions
- ER-100 epigenetic therapy
- Genetic
- Lead sponsor
- Life Biosciences Inc.
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 4
- States / cities
- Glendale, California • Boston, Massachusetts • New York, New York + 1 more
- Conditions
- Glaucoma Open-Angle Primary, Glaucoma, Open Angle Glaucoma, Glaucoma, Open-Angle
- Interventions
- Mitomycin C
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 20 Years to 85 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 4
- States / cities
- Arcadia, California • Fountain Valley, California • Los Angeles, California + 1 more
- Conditions
- Glaucoma, Open-Angle, Ocular Hypertension
- Interventions
- AGN-210669 ophthalmic solution, 0.1%, AGN-210669 ophthalmic solution, 0.075%, AGN-210669 ophthalmic solution, 0.05%, bimatoprost ophthalmic solution 0.03%
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Glaucoma, Open-angle, Ocular Hypertension (OHT), Phacoemulsification Cataract Surgery
- Interventions
- iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery, Sham procedure in conjunction with cataract surgery
- Combination Product · Procedure
- Lead sponsor
- Glaukos Corporation
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Kenosha, Wisconsin
- Conditions
- Open Angle Glaucoma, Ocular Hypertension
- Interventions
- Phentolamine Mesylate Ophthalmic Solution 1%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
- Drug · Other
- Lead sponsor
- Opus Genetics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 5
- States / cities
- Mission Hills, California • Morrow, Georgia • Ann Arbor, Michigan + 2 more
- Conditions
- Open Angle Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma
- Interventions
- iStent infinite trabecular micro-bypass system model iS3, iDose TR (Travoprost intracameral Implant) 75mcg
- Device · Drug
- Lead sponsor
- Jonathon Myers
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Glaucoma, Glaucoma, Open-Angle, Optic Nerve Diseases
- Interventions
- Repetitive, Transorbital Alternating Current Stimulation (rtACS)
- Device
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Glaucoma, Open-Angle, Ocular Hypertension
- Interventions
- AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo), timolol ophthalmic solution 0.5%, AGN-207281 vehicle ophthalmic solution (Placebo)
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Open-angle Glaucoma, Ocular Hypertension
- Interventions
- Bimatoprost Ophthalmic Solution, 0.01%, LUMIGAN® (bimatoprost ophthalmic solution) 0.01%
- Drug
- Lead sponsor
- Amneal Pharmaceuticals, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 4
- States / cities
- Bakersfield, California • Newport Beach, California • Morrow, Georgia + 1 more
- Conditions
- Ocular Hypertension, Open-angle Glaucoma
- Interventions
- Timolol maleate Ophthalmic Solution 0.5% BID, AR-13324 Ophthalmic Solution 0.02%, Placebo
- Drug · Other
- Lead sponsor
- Aerie Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 411 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Bedminster, New Jersey
- Conditions
- Aniridia, Eye Abnormality, Ocular Hypertension, Open Angle Glaucoma
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1977 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Glaucoma
- Interventions
- MINIject™ Implant
- Device
- Lead sponsor
- iSTAR Medical
- Industry
- Eligibility
- 46 Years and older
- Enrollment
- 975 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 28
- States / cities
- Glendale, Arizona • Fayetteville, Arkansas • Beverly Hills, California + 24 more
- Conditions
- Glaucoma, Primary Open Angle
- Interventions
- ELIOS Procedure
- Device
- Lead sponsor
- Elios Vision, Inc.
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 6
- States / cities
- Glendale, Arizona • Rock Island, Illinois • St Louis, Missouri + 3 more
- Conditions
- Glaucoma, Open-Angle, Glaucoma; Drugs
- Interventions
- dorzolamide/timolol
- Drug
- Lead sponsor
- CT Glaucoma Associates
- Other
- Eligibility
- 25 Years to 90 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Norwalk, Connecticut
- Conditions
- Open Angle Glaucoma, Ocular Hypertension
- Interventions
- PG286 Ophthalmic Solution 0.5%, AR-12286 Ophthalmic Solution 0.5%, Travoprost Ophthalmic Solution 0.004%
- Drug
- Lead sponsor
- Aerie Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 21
- States / cities
- Artesia, California • Inglewood, California • Newport Beach, California + 18 more
- Conditions
- Primary Open Angle Glaucoma
- Interventions
- Not listed
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 133 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Glaucoma, Open-Angle [C11.525.381.407]
- Interventions
- Open angle glaucoma - iDropper device
- Device
- Lead sponsor
- Care Team Solutions
- Industry
- Eligibility
- 21 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Open Angle Glaucoma, Ocular Hypertension
- Interventions
- PG324 Ophthalmic Solution 0.01%, PG324 Ophthalmic Solution 0.02%, Netarsudil (AR-13324) Ophthalmic Solution 0.02%, Latanoprost Ophthalmic Solution 0.005%
- Drug
- Lead sponsor
- Aerie Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 298 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 23
- States / cities
- Artesia, California • Inglewood, California • Newport Beach, California + 20 more
- Conditions
- Open-Angle Glaucoma, Ocular Hypertension
- Interventions
- Bimatoprost SR, Standard of Care
- Drug · Other
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 455 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 66
- States / cities
- Dothan, Alabama • Chandler, Arizona • Phoenix, Arizona + 60 more
- Conditions
- Glaucoma, Glaucoma, Open Angle
- Interventions
- AqueSys XEN 45 Glaucoma Implant
- Device
- Lead sponsor
- AqueSys, Inc.
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 12
- States / cities
- Glendale, Arizona • Fayetteville, Arkansas • Montebello, California + 9 more
- Conditions
- Glaucoma, Primary Open Angle, Ocular Hypertension
- Interventions
- WB007 0.05%, WB007 0.15%, WB007 0.4%, Timolol 0.5%
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Open Angle Glaucoma
- Interventions
- Acular LS, Pred Forte, Refresh Tears
- Drug · Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Glaucoma
- Interventions
- BL1107 Low dose, BL1107 High dose, Timolol maleate 0.5%
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 14
- States / cities
- Glendale, California • Newport Beach, California • Pasadena, California + 11 more